{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seethapathy H"],"funding":["Claflin Distinguished Scholars Award","NIDDK NIH HHS","National Institutes of Health"],"pagination":["507-514"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8875461"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(3)"],"pubmed_abstract":["<h4>Background</h4>Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.<h4>Methods</h4>We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.<h4>Results</h4>A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) expe"],"journal":["Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"],"pubmed_title":["Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib."],"pmcid":["PMC8875461"],"funding_grant_id":["K23 DK117014","K23 DK 117014","NIH"],"pubmed_authors":["Reynolds KL","Lee MD","Sise ME","Seethapathy H","Fadden RM","Rosales IA","Efe O","Chute DF","Kaufman HL","Colvin RB","Strohbehn IA","Jhaveri KD","Sullivan RJ","Rusibamayila N"],"additional_accession":[]},"is_claimable":false,"name":"Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.","description":"<h4>Background</h4>Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.<h4>Methods</h4>We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.<h4>Results</h4>A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) expe","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-03-27T16:43:21.944Z","creation":"2025-04-04T08:57:40.433Z"},"accession":"S-EPMC8875461","cross_references":{"pubmed":["33355659"],"doi":["10.1093/ndt/gfaa372"]}}